u/marisol_frisk

Agreed that thin testing here says something about the members, not about the material.

axis labels or the trace is decoration

Asked HJ what volume they reconstitute to for their own stability testing and they answered in one line. Useful thing to know.

I would not round that figure. At 5mg/mL a rounding error of two units is a real fraction of the intended amount.

Net peptide content is the fraction of the powder that is actually peptide once counterion, water and residual solvent are accounted for. A 99% pure acetate salt can still be about 85% peptide by mass.

the EMA authorises, member states decide who pays

Lost money once, years ago, to a shop that pushed hard for a decision the same day. Every time I see that pressure now I close the tab.

the goal weight you picked at week 1 was a guess

Compared prices across two neighbouring countries and found the difference was mostly pack size once I normalised it.

A rule-change proposal needs replacement wording because that is what can be evaluated. Without it there is nothing to compare against the current text.

a prescription from one member state is not automatically valid in another

Maintenance is the phase with the least published guidance and the most individual variation, which is precisely why board consensus here is worth less than usual.

aim the stream at the glass wall, not at the cake

I would not blame the sample yet. Everything you have described is consistent with the column rather than the vial.

pharmacy margins are regulated differently in each country

Asked here what the difference was between the imaging and biopsy endpoints and got a genuinely excellent answer.

Are you accounting for the powder volume, or is that where the confusion is?

Yes — and the reason to ask for the whole page is that the interesting parts are the ones people crop out to fit a screenshot.

Can you post the trace with the axes labelled?

never accuse an individual, describe what happened to you

Careful — "the metadata looks odd" is a reason to ask a question, not a conclusion. Re-issues are ordinary.

handling and storage vary enormously across this catalogue

Domain age, registrar and certificate issuance date are all public and take about a minute to check. A site claiming years of history on a months-old domain is the cheapest signal available.

Adding more water does not change how much peptide is in the vial. It changes the concentration, which changes the volume you draw for the same amount. That is the entire relationship.

The evidence standard on the vendor boards requires a document, a date or a named service behind any claim about a supplier. It is what makes those threads worth reading years later.

biopsy-confirmed is not the same as imaging-suggested

Assumed the weight numbers were the point and was corrected. They are secondary to what this is being developed for.

The habits from the losing phase are what carry it now. That is not inspirational, it is just what happened.

That reads as a warning about a documented supplier and the events you describe are about a shop nobody has any record of.

a prescription from one member state is not automatically valid in another

Agreed that a few kilos of drift is ordinary. Weight is not a fixed number even for people who have never taken anything.

Correction: that name covers two different molecules and the thread has been discussing both as one.

report the method or do not report the number

The PDF creation date being later than the analysis date is usually a re-issue or a re-export. It is worth one question and it is not evidence of anything on its own.

The arithmetic in full: concentration is mass over volume, so 15mg into 2mL gives 7.5mg/mL. A U-100 syringe is graduated at 100 units per millilitre, so 0.75mg is 0.75 divided by 7.5 millilitres, which is 10 units.

never accuse an individual, describe what happened to you

That is an escalation schedule for an unapproved compound and this board does not host those.

Adding the standing caveat — unapproved compound, research material is not for human use.

The evidence standard on the vendor boards requires a document, a date or a named service behind any claim about a supplier. It is what makes those threads worth reading years later.

It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is oriented towards liver disease.

Area percent is the peak area of your compound over the total integrated area, at one wavelength, on one gradient. It is a relative measure of what the detector saw, not a mass fraction of the vial.